| Date | Title | | | 12/13/07 | Nanosphere, Inc. Announces Third Quarter 2007 Financial Results| Initiates Commercial Launch of the Verigene(R) System
NORTHBROOK, Ill., Dec 13, 2007 (BUSINESS WIRE) -- Nanosphere, Inc. (NASDAQ: NSPH), a leader in the development and
commercialization of advanced molecular diagnostics systems, today
reported financial results for the third quarter ended September 30,
2007.
Third quarter 2007 results reflect investments associated with the
commercial launch of the Verigene platform and its initial menu of
tests, as well as significant non-cash charges a... |
|  | | 12/06/07 | Nanosphere to Report 3rd Quarter Results & Hold Investor Conference Call on Thursday, December 13, 2007| NORTHBROOK, Ill.--(BUSINESS WIRE)--Dec. 6, 2007--Nanosphere, Inc.,
(NASDAQ: NSPH), which develops, manufactures and markets advanced
molecular diagnostics systems, will announce its results for the third
quarter of 2007 prior to the market opening on Thursday, December 13,
2007. The company will also hold a live conference call and webcast
for investors that morning at 10:30 A.M., Eastern Standard Time.
The teleconference can be accessed by dialing 866-510-0705
(U.S./Canada) or 61... |
| | | 11/06/07 | Nanosphere Announces Exercise of Over-Allotment Option and Closing of Initial Public Offering| NORTHBROOK, Ill., Nov 06, 2007 (BUSINESS WIRE) -- Nanosphere, Inc. (NASDAQ: NSPH), a nanotechnology-based molecular
diagnostics company, today announced that the underwriters of
Nanosphere's recent initial public offering of its common stock
exercised in full their over-allotment option to purchase an
additional 1,050,000 shares of Nanosphere's common stock at $14.00 per
share, less underwriting discounts and commissions. The option was
granted in connection with Nanosphere's initial publi... |
| | | 11/01/07 | Nanosphere Announces Initial Public Offering| NORTHBROOK, IL.—November 1, 2007—Nanosphere, Inc., a nanotechnology-based molecular diagnostics company, today announced the pricing of its initial public offering of 7,000,000 shares of its common stock at $14.00 per share. All of the shares are being offered by Nanosphere. Nanosphere has granted to the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. Nanosphere's c... |
| | | 10/16/07 | Nanosphere Announces FDA Clearance of Second Molecular Diagnostics Assay| Hyper-coagulation Panel Designed to Test for Blood Coagulation Disorders
NORTHBROOK, IL—October 16, 2007—Nanosphere, Inc., a nanotechnology-based molecular diagnostics company, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for the Verigene® F5 / F2 / MTHFR Nucleic Acid Test, which detects disease-associated gene mutations that can contribute to blood coagulation disorders and difficulties metabolizing folate (vitamin B-12). This marks the sec... |
| | | 09/18/07 | Nanosphere Announces First FDA Cleared Genetic Test for Warfarin Sensitivity and Nanotechnology-based Molecular Diagnostics Platform| Verigene® System Designed to Make Genetic Testing Simpler and More Accessible
NORTHBROOK, IL—September 18, 2007—Nanosphere, Inc., a nanotechnology-based molecular diagnostics company, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for the Verigene® System, a random access, molecular diagnostics workstation for nucleic acid and protein diagnostics. The company also announced FDA clearance of the Verigene® System's first test to determine an indi... |
| |
|
